Taiwan-based Foresee Pharmaceuticals has been notified by its licensing partner, Changchun GeneScience Pharmaceutical (GenSci), that China's National Medical Products Administration (NMPA) has approved the Marketing Authorisation Application (MAA) for CAMCEVI® 42 mg, a ready-to-use 6-month subcutaneous depot formulation of leuprolide mesylate, for the treatment of adult patients with advanced prostate cancer.
CAMCEVI® is exclusively licensed to GenSci for commercialisation in China across all current and pipeline indications, including advanced prostate cancer, central precocious puberty (CPP), and premenopausal breast cancer.
In addition to the NMPA's approval of CAMCEVI® 42 mg for advanced prostate cancer described above, GenSci submitted a supplemental New Drug Application (sNDA) in May 2026 for leuprolide mesylate injectable emulsion for the additional indication of premenopausal breast cancer, which has been accepted by the NMPA for substantive review.
It is approved for the treatment of adult patients with advanced prostate cancer in the United States (since May 2021), the European Union (since May 2022), and other markets.
